Cobalamin acquisition protein and use thereof
US-9234012-B2 · Jan 12, 2016 · US
US9758550B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758550-B2 |
| Application number | US-201514958321-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 3, 2015 |
| Priority date | Apr 30, 2012 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a cobalamin acquisition protein, compositions containing the cobalamin acquisition protein, and the use of such compositions.
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a protein that binds Vitamin B 12 , said protein comprising an amino acid sequence having at least 90% identity with SEQ ID NO: 2, and a pharmaceutically acceptable excipient. 2. The composition of claim 1 , wherein the protein binds Vitamin B 12 with an affinity less than 10 −5 M. 3. The composition of claim 1 , wherein the composition is a liquid, solid, cream, or paste. 4. The composition of claim 1 , wherein the protein binds Vitamin B 12 with an affinity from about 10 −5 M to about 10 −12 M. 5. The composition of claim 1 , wherein the composition, when administered to a subject, is capable of reducing the growth and/or proliferation of a microorganism in or on the subject. 6. The composition of claim 1 , wherein the protein comprises from about 0.1% (w/w) to about 90% (w/w) of the pharmaceutical composition. 7. The composition of claim 6 , wherein the protein comprises from about 0.5% (w/w) to about 30% (w/w) of the pharmaceutical composition. 8. A method of treating a bacterial infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 1 . 9. The method of claim 8 , wherein the composition is administered topically or orally to the subject. 10. The method of claim 8 , wherein the composition is administered non-parenterally to the subject.
involving vitamins {or their receptors} · CPC title
Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title
from invertebrates · CPC title
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof · CPC title
from algae · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.